Monte Rosa Therapeutics

Monte Rosa Therapeutics

Markus Warmuth, a former H3 Biomedicine executive, co-founded Monte Rosa Therapeutics in 2019 within Versant Venture's Ridgeline Discovery Engine in Basel before establishing a Boston headquarters. The firm emerged from seed-stage incubation at Versant's Basel innovation hub, which systematically builds single-asset therapeutics companies around specific biological mechanisms. Warmuth and CSO Peter Hammerman designed Monte Rosa around the premise that protein degradation could be rationally engineered rather than discovered by chance — a departure from the serendipitous discovery that produced earlier molecular glues like lenalidomide. Monte Rosa directs its QuEEN platform toward high-value protein targets across oncology, autoimmune disease, and neurology. The platform integrates AI-based structural modeling, quantitative proteomics, and chemical biology to identify surface-exposed pockets on target proteins that recruit E3 ubiquitin ligases for degradation. The firm's lead candidate, MRT-2359, targets the GSPT1 protein in MYC-driven solid tumors and entered a Phase 1/2 clinical trial in 2022. Additional pipeline programs address targets in immunology and inflammation, including an NEK7 degrader. Monte Rosa has disclosed a collaboration with Roche, signed in October 2023, to develop molecular glue degraders against cancer and neurological disease targets — a deal carrying up to $2 billion in potential milestone payments. Monte Rosa operates from a discovery hub in Basel, Switzerland and a corporate and translational science headquarters in Boston. The firm raised a $96 million Series C round in March 2021, followed by a $222 million IPO in June 2021 on NASDAQ, with backing from Versant Ventures, New Enterprise Associates, Cormorant Asset Management, and others. In October 2023, the firm signed the multi-target strategic collaboration with Roche, a significant de-risking event that validated the platform's industrial utility and provided non-dilutive capital during a tight biotech funding cycle. Monte Rosa's structural distinction lies in its systematic approach to designing heterobifunctional degraders — molecules with two distinct heads that bind a target and an E3 ligase simultaneously — an advance beyond serendipitous monovalent molecular glues. The QuEEN platform generates large, proprietary chemical libraries to explore the ternary complexes that form between ligase, degrader, and target, compressing the cycle from hit-finding to lead optimization. The dual-hub structure, split between Roche's Basel backyard and Boston's Kendall Square ecosystem, creates a talent and partnering advantage unavailable to firms anchored to a single geography.